Biogen Alzheimer's drug appears to have setback as FDA advisers recommend not to approveMarket Watch • 11/06/20
Biogen Stock Halted As FDA Panel Prepares To Discuss Alzheimer's DrugInvestors Business Daily • 11/06/20
Biogen's stock is halted as FDA committee convenes on experimental Alzheimer's disease treatmentMarket Watch • 11/06/20
Signs point to FDA approval for Biogen's experimental Alzheimer's disease treatment, though there are skepticsMarket Watch • 11/05/20
Is Biogen Stock A Buy As FDA Panel Considers Key Alzheimer's Drug?Investors Business Daily • 11/04/20
Biogen soars 47% after FDA scientists say its Alzheimer's drug's efficacy is 'exceptionally persuasive' (BIIB)Business Insider • 11/04/20
Biogen just gained $16 billion in market value, as investors increasingly expect approval of the first Alzheimer's drug in over 15 years. Here's what comes next.Business Insider • 11/04/20
Biogen's stock soars 42% in advance of FDA meeting on its Alzheimer's disease therapy candidateMarket Watch • 11/04/20
Biogen's stock jumps 30% after FDA staff says it has enough data to support approving Alzheimer's drugCNBC • 11/04/20